Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Products
Alnylam Announces FDA Approval Of Amvuttra (Vutrisiran)
Published: 06/13/2022 23:28 GMT
Alnylam Pharmaceuticals Inc (ALNY) - Alnylam Announces FDA Approval of Amvuttra™ (vutrisiran), an Rnai Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-mediated Amyloidosis in Adults.
Amvuttra Met Primary and All Secondary Endpoints, With Significant Improvement in Polyneuropathy.company Expects to Launch Amvuttra in Early July.
Amvuttra Met Primary and All Secondary Endpoints, With Significant Improvement in Polyneuropathy.company Expects to Launch Amvuttra in Early July.